Almirall launches Parapres Plus 32 and Parapres Plus Forte

Almirall has launched two new treatments for people who suffer from arterial hypertension.

In a statement, the international pharmaceutical organisation explained that Parapres Plus 32 and Parapres Plus Forte are indicated for patients who have high blood pressure (HBP) that cannot be sufficiently controlled with monotherapy.

The firm noted that the two combinations contain candesartan cylexetile, which offers high organic protection and has received support from a range of studies that have been performed on patients with conditions as diverse as kidney damage and cardiac insufficiency.

Almirall said that arterial hypertension treatment aims to reduce the cardiovascular morbimortality that is associated with HBP.

It added: “The general recommendation is to reduce HBP to below 140/90 mmHg. For patients with cardiovascular disease, diabetes or nephropathy it is reasonable to reduce HBP to figures below 130/80 mmHg3.”

Last month, Almirall announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for its silodosin product.